A Multiple-Dose Targeting Study of hu3S193 in Patients With Small Cell Lung Cancer
- Determine the targeting, tissue distribution, and pharmacokinetics of monoclonal
antibody Hu3S193 in patients with progressive small cell lung cancer.
- Determine the immunogenicity of this drug in these patients.
- Determine tumor response in patients treated with this drug.
- Determine the safety of this drug in these patients.
OUTLINE: This is an open-label, pilot study.
Patients receive monoclonal antibody Hu3S193 (MOAB Hu3S193) IV over 30 minutes on day 1 of
weeks 1-4. Patients also receive indium In III MOAB Hu3S193 IV over 30 minutes on day 1 of
weeks 1 and 4 and then undergo gamma camera imaging. Treatment continues in the absence of
disease progression or unacceptable toxicity.
Patients are followed at 1 and 4 weeks, every 3 months for 1 year, and then every 6-12
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Lee M. Krug, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|